Skip to main navigation Skip to search Skip to main content

Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG)

  • Kimberley Doucette
  • , Christin B DeStefano
  • , Natasha A Jain
  • , Allan L Cruz
  • , Vera Malkovska
  • , Kelly Fitzpatrick

Research output: Contribution to journalArticlepeer-review

Abstract

Delayed onset heparin induced thrombocytopenia (HIT), is characterized by a late nadir due to persistent platelet-activating IgG antibodies. It typically begins or worsens 5 or more days after heparin is discontinued with complications such as thrombosis up to 3 weeks after exposure to heparin. 1-3 In 50% of cases, the platelet count can decrease to very low numbers (<20 000/μL), which is not usual for typical HIT. Here we report 2 cases of post-operative delayed onset HIT manifesting as severe thrombocytopenia that persisted despite cessation of heparin and initiation of argatroban. Key Clinical Question: Is intravenous immunoglulin beneficial in severe refractory delayed-onset HIT?

Original languageEnglish
Pages (from-to)134-137
Number of pages4
JournalResearch and Practice in Thrombosis and Haemostasis
Volume1
Issue number1
DOIs
StatePublished - Jul 2017

Fingerprint

Dive into the research topics of 'Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG)'. Together they form a unique fingerprint.

Cite this